Non-peptidic GLP-1R agonists represent a promising class of therapeutic agents for T2DM and obesity, offering the potential advantages of oral bioavailability and convenient dosing over traditional peptide-based GLP-1R agonists. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.